ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Hot Features

Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

NRSN NeuroSense Therapeutics Ltd

1,08
-0,06 (-5,26%)
Última atualização: 16:41:42
Atrasado em 15 minutos
Nome da Ação Código da Ação Bolsa de Valores Tipo de Ativo
NeuroSense Therapeutics Ltd NRSN NASDAQ Ordinária
  Variação do Dia (p) Variação do Dia % Último Preço Hora
-0,06 -5,26% 1,08 16:41:42
Preço de Abertura Preço Mínimo Preço Máximo Fech. Hoje Fech. Anterior
1,11 1,08 1,13 1,14
mais cotações »

Notícias Recentes

Data Hora Fonte Título
20/05/202410:00PRNUSNeuroSense Vice President of R&D Shiran Zimri, Ph.D. to..
14/05/202410:05PRNUSNeuroSense Partners with PhaseV to Optimize Upcoming ALS..
07/05/202409:45PRNUSNeuroSense Announces New Positive Data Analysis from..
02/05/202410:19PRNUSNeuroSense Announces First Quarter 2024 Business Update
22/04/202409:30PRNUSNeuroSense and Genetika+ Initiate Precision Medicine..
18/04/202409:30PRNUSNeuroSense Presents Positive Data Validating Phase 2b..
12/04/202409:30PRNUSNeuroSense to Present PARADIGM Data at the American Academy..
10/04/202420:16PRNUSNeuroSense Announces Pricing of $4.5 Million Registered..
09/04/202409:30PRNUSNeuroSense Collaborates with Lonza to Identify Exosome-based..
05/04/202410:29PRNUSNeuroSense Announces Year End 2023 Financial Results and..
21/02/202410:30PRNUSNeuroSense Reports Additional Positive Results from its ALS..
07/02/202411:27PRNUSNeuroSense Regains Compliance with NASDAQ Minimum Bid Price..
09/01/202410:45PRNUSNeuroSense Recaps Positive 2023 Achievements Including..
27/12/202319:00PRNUSNeuroSense Announces Receipt of Nasdaq Notice Regarding..
14/12/202311:24PRNUSNeuroSense Reports New Data: Statistically Significant..
05/12/202310:00PRNUSNeuroSense's Phase 2b ALS Trial Achieves Primary Safety and..
04/12/202318:01PRNUSNeuroSense to Report Phase 2b ALS Topline Primary Safety and..
28/11/202310:45PRNUSNeuroSense Announces Third Quarter 2023 Financial Results..
13/11/202311:20PRNUSNeuroSense Receives U.S. FDA Confirmation of CMC Strategy..
09/11/202311:00PRNUSNeuroSense Therapeutics to Present at Upcoming U.S. and..
06/11/202310:30PRNUSNeuroSense Completes Dosing of Last Patient in the..
01/11/202310:00PRNUSNeuroSense Therapeutics to Participate in BIO-Europe Fall
17/10/202309:30PRNUSNeuroSense CEO Provides Q3 2023 Update
04/10/202310:10PRNUSNeuroSense's PrimeC Demonstrates Outstanding Effect on ALS..
20/09/202310:05PRNUSEuropean Medicines Agency Grants NeuroSense SME Status
19/09/202310:00PRNUSNeuroSense Granted Patents in Europe, Japan, and Israel for..
14/09/202310:00PRNUSNeuroSense to Participate in Upcoming ALS Conferences:..
06/09/202309:30PRNUSNeuroSense to Host Investor Webinar on September 12, 2023
16/08/202310:00PRNUSNeuroSense Announces Second Quarter 2023 Financial Results..
17/07/202309:30PRNUSNeuroSense to Host Investor Event in Cambridge,..
11/07/202310:00PRNUSNeuroSense to Participate in Upcoming ALS Conferences:..
06/07/202309:30PRNUSNeuroSense CEO Provides Q2 2023 Update
22/06/202309:30PRNUSNeuroSense Announces Pricing of $4.5 Million Registered..